Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07287176 · ClinicalTrials.gov registry record · NA

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System

A NA study of Thyroid Nodule and Ablation, sponsored by Pulse Biosciences.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
2
Study locations

NCT07287176 is a NA study of Thyroid Nodule and Ablation that is actively recruiting participants, run by Pulse Biosciences. The registered enrollment target is 100 participants, above the 64-participant average among 5 other Thyroid Nodule trials with a reported enrollment target (56% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07287176, a NA study of Thyroid Nodule and Ablation, is actively recruiting participants, sponsored by Pulse Biosciences.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
2
Study locations

Study Summary

The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life post-ablation using a validated QoL questionnaire.

Interventions

  • DEVICE nPulse Vybrance Percutaneous Electrode System

Study Locations (2)

Florida

  • Sarasota Memorial Hospital - Sarasota

New York

  • Weill Cornell Medicine - New York

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-08-21
Est. Completion 2027-02
Phase NA

Sponsor

Pulse Biosciences

10 total trials

What the Registry Record Tells You About NCT07287176

The ClinicalTrials.gov registry entry for NCT07287176 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 64-participant average among 5 other Thyroid Nodule trials with a reported enrollment target (56% higher). The listed sponsor is Pulse Biosciences, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Thyroid Nodule appearing as the primary indexed condition, and to 1 intervention - of which nPulse Vybrance Percutaneous Electrode System is the first listed.

NCT07287176 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, New York.

Frequently Asked Questions

What is clinical trial NCT07287176 about?

NCT07287176 is a clinical study titled "Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System". The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life p...

What is the current status of trial NCT07287176?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-08-21. Estimated completion is 2027-02.

What conditions does trial NCT07287176 study?

This clinical trial studies the following conditions: Thyroid Nodule, Ablation, Thyroid Goiter.

What interventions are being tested in trial NCT07287176?

The interventions under investigation include: nPulse Vybrance Percutaneous Electrode System (DEVICE).

Who is sponsoring clinical trial NCT07287176?

This trial is sponsored by Pulse Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07287176 being conducted?

This trial has 2 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Thyroid Nodule

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.